(MENAFN- GlobeNewsWire - Nasdaq) Opportunities span organ-on-chip, kidney organoid, AI prediction, biomarker panels and high-throughput screening, driven by kidney disease and demand for safer, animal-free drug testing.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Renal Toxicity - Absorption, Distribution, Metabolism, and Excretion (ADME) Toxicology Testing Market Report 2026" has been added to ResearchAndMarkets.com's offering.
The global renal toxicity absorption, distribution, metabolism, and excretion (ADME) toxicology testing market is projected to expand rapidly as pharmaceutical and biotechnology companies strengthen drug safety assessment and adopt advanced predictive testing technologies. The market is expected to grow from $1.52 billion in 2025 to $1.71 billion in 2026, representing a compound annual growth rate (CAGR) of 12.7%.
By 2030, the renal toxicity ADME toxicology testing market is forecast to reach $2.78 billion, advancing at a CAGR of 12.9%. Historical growth has been supported by increasing preclinical drug safety testing, a rise in nephrotoxicity-related drug failures, expansion of contract research organization services, stricter regulatory safety requirements and broader adoption of in vitro assays.
Future market growth is expected to be driven by the development of biologics and complex therapeutics, increasing use of predictive toxicology models, expansion of organ-on-chip platforms, growth in precision medicine research and rising demand for artificial intelligence-based safety analytics. Prominent renal toxicity testing market trends include kidney organoid assays, AI-assisted nephrotoxicity prediction, high-throughput renal screening, biomarker-driven safety panels and microphysiological kidney-on-chip systems.
The increasing prevalence of kidney-related disorders is a major factor supporting demand for renal toxicity ADME toxicology testing. Rising diabetes rates and other chronic health conditions are contributing to a growing burden of renal disease, intensifying the need for safer medicines and earlier identification of kidney-related drug risks. These testing services help researchers evaluate potential renal damage associated with pharmaceutical compounds and chemicals, supporting more informed decisions throughout drug development.
According to the American Cancer Society, approximately 80,980 new kidney cancer cases are projected to be diagnosed in the United States in 2025, with an estimated 14,510 deaths. The scale of kidney-related disease is encouraging pharmaceutical developers, biotechnology companies, research institutions and regulators to prioritize renal safety evaluation and improve the predictive accuracy of preclinical testing.
Technological innovation is reshaping the renal toxicity ADME toxicology testing market. In September 2024, Emulate Inc. launched its Chip-R1 rigid chip to support more accurate ADME and toxicology modeling in non-stretch organs, including the kidney and liver. The platform uses low-drug-absorbing plastics and a thin, porous polycarbonate membrane to reduce compound loss and improve drug recovery, particularly for lipophilic compounds.
The Chip-R1 platform also supports shear stress of up to 2.3 dyn/cm, offers preactivated surfaces to simplify laboratory workflows and facilitates improved cellular communication. These capabilities are designed to increase reproducibility, strengthen toxicity detection and support compatibility with existing organ-chip hardware. Such developments are accelerating the transition toward human-relevant preclinical models while reducing dependence on animal testing.
Strategic collaborations are further advancing the market. In April 2025, CN Bio Innovations Ltd. partnered with Pharmaron Beijing Co. Ltd. to implement the PhysioMimix organ-on-chip platform across Pharmaron's global research and development facilities. The collaboration covers toxicity assessment, renal applications, ADME studies, disease modeling and the co-development of human-relevant models for drug discovery and development.
Tariffs are also affecting the renal toxicity testing industry by increasing the cost of imported laboratory instruments, assay kits, imaging systems, reagents and microfluidic devices. Contract research organizations and advanced testing laboratories that rely on specialized imported equipment are experiencing higher operating expenses and pressure on expansion budgets. In vitro testing and organ-on-chip segments remain particularly exposed because of their dependence on sophisticated hardware. However, these trade pressures are also encouraging domestic production of laboratory consumables, analytical instruments and supporting technologies.
The renal toxicity ADME toxicology testing market includes in vitro testing, in vivo testing and in silico modeling. Key applications span discovery and lead optimization, preclinical development, clinical development and post-marketing safety studies. Technologies used across the market include high-throughput screening, microfluidic systems, organ-on-chip platforms, omics-based toxicology, predictive modeling, artificial intelligence, digital pathology and advanced imaging. Principal end users include pharmaceutical and biotechnology companies, contract research organizations, academic and research institutes, and regulatory laboratories.
The market analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Country-level coverage includes Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan, Russia, South Korea, Spain, Canada, the United Kingdom and the United States.
Markets Covered:
1) By Test Type: In Vitro Renal Toxicity Testing; In Vivo Renal Toxicity Testing; In Silico Renal Toxicity Modeling
2) By Method: Biochemical and Enzymatic Assays; Cell Based Renal Assays; Biomarker Based Toxicity Analysis; Histopathology and Imaging; Pharmacokinetic and Drug Metabolism Studies
3) By Stage of Drug Development: Discovery and Lead Optimization; Preclinical Development; Clinical Development; Post Marketing Safety Studies
4) By Technology: High Throughput Screening Platforms; Organ On Chip and Microfluidic Systems; Omics Based Toxicology Platforms; Artificial Intelligence and Predictive Modeling Tools; Digital Pathology and Imaging Systems
5) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations; Academic and Research Institutes; Regulatory Laboratories
Subsegments:
1) By In Vitro Renal Toxicity Testing: Primary Renal Cell Assays; Immortalized Renal Cell Line Assays; Three Dimensional Renal Cell Cultures; Kidney Organoid Models; Transporter Interaction Assays; Biomarker Based Nephrotoxicity Assays; High Content Imaging Assays; Microphysiological Kidney System Models
2) By In Vivo Renal Toxicity Testing: Acute Renal Toxicity Studies; Subacute Renal Toxicity Studies; Subchronic Renal Toxicity Studies; Chronic Renal Toxicity Studies; Renal Biomarker Evaluation Studies; Histopathological Kidney Assessment; Dose Response Toxicity Studies; Recovery and Reversibility Studies
3) By In Silico Renal Toxicity Modeling: Quantitative Structure Activity Relationship Modeling; Machine Learning Based Toxicity Prediction; Physiologically Based Pharmacokinetic Modeling; Virtual Screening for Nephrotoxicity; Read Across Toxicity Modeling; Systems Biology Based Toxicity Modeling
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment